Syndax Pharmaceuticals stock
SNDXNASDAQSyndax Pharmaceuticals, Inc., HealthcareISIN US87164F1057
33Score 33 out of 100, Weak
Price and trend
28 / 100
Price history
−43% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 52% below it.
Since August 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Sharply down: the price has fallen very quickly lately (RSI 29).
The price is 62% below its 52-week high. Largest decline in 11 years: 79% (August 2016 to December 2018).
Chart figures for advanced users
- SMA 50$15.50
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$19.78
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)29
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$9.37
- The lowest closing price of the last twelve months.
- Resistance$25.15
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Syndax Pharmaceuticals, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $858.87M, is number 200 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $172.35M (up 627.8% year on year) and a loss of $285.42M.
- For fiscal 2026, analysts expect on average revenue of $314.38M (up 82.4%) and adjusted earnings per share of −$2.15.
Show more
- MEQIRI Score 33 out of 100 (Weak): rank 649 of 702 in Healthcare, median 53.
- Our model puts fair value at $29.43, with the price 68% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- DilutionShare count up 110% since 2020.Capital allocation 18
- Loss-makingLoss of $209.48M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$177.46M over the last 12 months.Fundamentals 17
Its standout strength is valuation, while fundamentals and momentum hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- price far below its 52-week high
- high price swings
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $21.02 and expensive above $49.06 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 12%. At 13% the fair value would be $25.01, at 11% it would be $35.17.
Possible value trap: looks cheap, but score below 50, high risk, weak balance sheet.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Sep 2026, revenue rose 81.6% on the same quarter a year earlier. Revenue has grown strongly since 2024, at around 628% per year. From 2024 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 96%, operating −158%, net −166%. Last 12 months: net −72%. From 2024 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 104 days
- Last reported
- 2 Nov 2026EPS reported −$0.55 (expected −$0.50)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 20.5% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$2.15−6.5%
- Revenue
- $314.38M+0.1%
- Earnings per share
- −$0.98−20.5%
- Revenue
- $457.9M−0.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +0.2%No financial guidance; the Niktimvo margin contribution is expected to stay in the 25% to 30% range near term and several data readouts are expected in the fourth quarter.
“We expect Niktimvo margin contribution, defined as the collaboration revenue recorded by Syndax as a percentage of Niktimvo net sales, to continue to be in the 25% to 30% range in the near term and increase longer term as sales grow.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 3 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $2.23M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Syndax Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 33
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- 4D Molecular TherapeuticsFDMT $875.68M47
- Aktis OncologyAKTS $875M36
- Climb BioCLYM $869.94M41
- Rigel PharmaceuticalsRIGL $860.34M71
- MeiraGTx HoldingsMGTX $844.22M40
- AnnexonANNX $812.47M36
- Lexicon PharmaceuticalsLXRX $810.33M39
- Arbutus BiopharmaABUS $798.37M66
ETFs that hold Syndax Pharmaceuticals
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 1.26% | 0.49% | €26.29M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.08% | 0.40% | €1.5B |
| iShares Ageing Population UCITS ETF2B77 | 0.07% | 0.40% | €813.42M |
Show 5 more
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.05% | 0.35% | €1.25B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.03% | 0.30% | €2.22B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.02% | 0.30% | €185.82M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.54B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 28 Feb 2023)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.